{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T15:15:28Z","timestamp":1787584528693,"version":"build-2736575974"},"reference-count":40,"publisher":"Spandidos Publications","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.3892\/ol.2015.3253","type":"journal-article","created":{"date-parts":[[2015,5,22]],"date-time":"2015-05-22T05:49:57Z","timestamp":1432273797000},"page":"761-767","source":"Crossref","is-referenced-by-count":16,"title":["Acquired resistance to decitabine and cross-resistance to gemcitabine during the long-term treatment of human HCT116 colorectal cancer cells with decitabine"],"prefix":"10.3892","volume":"10","author":[{"given":"MIKA","family":"HOSOKAWA","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MAI","family":"SAITO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AIKO","family":"NAKANO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SAKURA","family":"IWASHITA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AYANO","family":"ISHIZAKA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KUMIKO","family":"UEDA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SEIGO","family":"IWAKAWA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2015,5,22]]},"reference":[{"key":"key20180108100829_b1-ol-0-0-3253","doi-asserted-by":"crossref","first-page":"21087","DOI":"10.3390\/ijms141021087","article-title":"Cancer development, progression, and therapy: An epigenetic overview","volume":"14","author":"Sarkar","year":"2013","journal-title":"Int J Mol Sci"},{"key":"key20180108100829_b2-ol-0-0-3253","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s10147-013-0651-5","article-title":"Novel therapeutic strategies using hypomethylating agents in the treatment of myelodysplastic syndrome","volume":"19","author":"Ishikawa","year":"2014","journal-title":"Int J Clin Oncol"},{"key":"key20180108100829_b3-ol-0-0-3253","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1177\/1087057111421212","article-title":"Epigenetic drug discovery: Targeting DNA methyltransferases","volume":"17","author":"Foulks","year":"2012","journal-title":"J Biomol Screen"},{"key":"key20180108100829_b4-ol-0-0-3253","doi-asserted-by":"crossref","first-page":"5483","DOI":"10.1038\/sj.onc.1205699","article-title":"5-Azacytidine and 5-aza-2\u2032-deoxycytidine as inhibitors of DNA methylation: Mechanistic studies and their implications for cancer therapy","volume":"21","author":"Christman","year":"2002","journal-title":"Oncogene"},{"key":"key20180108100829_b5-ol-0-0-3253","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.drup.2012.03.002","article-title":"Collateral sensitivity as a strategy against cancer multidrug resistance","volume":"15","author":"Pluchino","year":"2012","journal-title":"Drug Resist Updat"},{"key":"key20180108100829_b6-ol-0-0-3253","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.ctrv.2007.01.009","article-title":"Oxaliplatin for the treatment of cisplatin-resistant cancer: A systematic review","volume":"33","author":"Stordal","year":"2007","journal-title":"Cancer Treat Rev"},{"key":"key20180108100829_b7-ol-0-0-3253","first-page":"633","article-title":"The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells","volume":"31","author":"Fedier","year":"2007","journal-title":"Int J Oncol"},{"key":"key20180108100829_b8-ol-0-0-3253","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/CAD.0b013e3283262a32","article-title":"Acquired vorinostat resistance shows partial cross-resistance to \u2018second-generation\u2019 HDAC inhibitors and correlates with loss of histone acetylation and apoptosis but not with altered HDAC and HAT activities","volume":"20","author":"Dedes","year":"2009","journal-title":"Anticancer Drugs"},{"key":"key20180108100829_b9-ol-0-0-3253","first-page":"631","article-title":"MLH1 protects from resistance acquisition by the histone deacetylase inhibitor trichostatin A in colon tumor cells","volume":"35","author":"Imesch","year":"2009","journal-title":"Int J Oncol"},{"key":"key20180108100829_b10-ol-0-0-3253","doi-asserted-by":"crossref","first-page":"e23372","DOI":"10.1371\/journal.pone.0023372","article-title":"Mechanisms of resistance to decitabine in the myelodysplastic syndrome","volume":"6","author":"Qin","year":"2011","journal-title":"PLoS One"},{"key":"key20180108100829_b11-ol-0-0-3253","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1182\/blood-2008-02-140038","article-title":"Mechanisms of resistance to 5-aza-2\u2032-deoxycytidine in human cancer cell lines","volume":"113","author":"Qin","year":"2009","journal-title":"Blood"},{"key":"key20180108100829_b12-ol-0-0-3253","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.exphem.2013.12.004","article-title":"Mechanisms of resistance to azacitidine in human leukemia cell lines","volume":"42","author":"Sripayap","year":"2014","journal-title":"Exp Hematol"},{"key":"key20180108100829_b13-ol-0-0-3253","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1158\/1078-0432.CCR-12-1722","article-title":"Increased CDA expression\/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy","volume":"19","author":"Mahfouz","year":"2013","journal-title":"Clin Cancer Res"},{"key":"key20180108100829_b14-ol-0-0-3253","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1080\/15257770.2011.652330","article-title":"Role of human nucleoside transporters in the uptake and cytotoxicity of azacitidine and decitabine","volume":"31","author":"Damaraju","year":"2012","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"key20180108100829_b15-ol-0-0-3253","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1124\/mol.113.086801","article-title":"The role of human equilibrative nucleoside transporter 1 on the cellular transport of the DNA methyltransferase inhibitors 5-azacytidine and CP-4200 in human leukemia cells","volume":"84","author":"Hummel-Eisenbeiss","year":"2013","journal-title":"Mol Pharmacol"},{"key":"key20180108100829_b16-ol-0-0-3253","doi-asserted-by":"crossref","first-page":"3868","DOI":"10.1111\/bph.12748","article-title":"Nucleoside transporters and human organic cation transporter 1 determine the cellular handling of DNA-methyltransferase inhibitors","volume":"171","author":"Arimany-Nardi","year":"2014","journal-title":"Br J Pharmacol"},{"key":"key20180108100829_b17-ol-0-0-3253","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2217\/epi.09.44","article-title":"Will DNA methylation inhibitors work in solid tumors? A review of the clinical experience with azacitidine and decitabine in solid tumors","volume":"2","author":"Cowan","year":"2010","journal-title":"Epigenomics"},{"key":"key20180108100829_b18-ol-0-0-3253","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/nrclinonc.2013.42","article-title":"The future of epigenetic therapy in solid tumours - lessons from the past","volume":"10","author":"Azad","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"key":"key20180108100829_b19-ol-0-0-3253","doi-asserted-by":"crossref","first-page":"e92305","DOI":"10.1371\/journal.pone.0092305","article-title":"DNA methyltransferase inhibitors improve the effect of chemotherapeutic agents in SW48 and HT-29 colorectal cancer cells","volume":"9","author":"Flis","year":"2014","journal-title":"PLoS One"},{"key":"key20180108100829_b20-ol-0-0-3253","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1248\/bpb.b13-00574","article-title":"Different effects of epigenetic modifiers on the cytotoxicity induced by 5-fluorouracil, irinotecan or oxaliplatin in colon cancer cells","volume":"37","author":"Ikehata","year":"2014","journal-title":"Biol Pharm Bull"},{"key":"key20180108100829_b21-ol-0-0-3253","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/nrc1799","article-title":"Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction?","volume":"6","author":"Baylin","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"key20180108100829_b22-ol-0-0-3253","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1038\/oncsis.2013.35","article-title":"Epigenetic and genetic features of 24 colon cancer cell lines","volume":"2","author":"Ahmed","year":"2013","journal-title":"Oncogenesis"},{"key":"key20180108100829_b23-ol-0-0-3253","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/nrc1507","article-title":"CpG island methylator phenotype in cancer","volume":"4","author":"Issa","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"key20180108100829_b24-ol-0-0-3253","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1248\/bpb.25.1604","article-title":"MDR1-mediated interaction of digoxin with antiarrhythmic or antianginal drugs","volume":"25","author":"Kakumoto","year":"2002","journal-title":"Biol Pharm Bull"},{"key":"key20180108100829_b25-ol-0-0-3253","doi-asserted-by":"crossref","first-page":"e898","DOI":"10.1371\/journal.pone.0000898","article-title":"Evidence based selection of housekeeping genes","volume":"2","author":"de Jonge","year":"2007","journal-title":"PLoS One"},{"key":"key20180108100829_b26-ol-0-0-3253","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2144\/05391RV01","article-title":"Real-time PCR for mRNA quantitation","volume":"39","author":"Wong","year":"2005","journal-title":"Biotechniques"},{"key":"key20180108100829_b27-ol-0-0-3253","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/ng1330","article-title":"Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer","volume":"36","author":"Suzuki","year":"2004","journal-title":"Nat Genet"},{"key":"key20180108100829_b28-ol-0-0-3253","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/sj.bjc.6603860","article-title":"Pharmacogenomics of gemcitabine: Can genetic studies lead to tailor-made therapy?","volume":"97","author":"Ueno","year":"2007","journal-title":"Br J Cancer"},{"key":"key20180108100829_b29-ol-0-0-3253","first-page":"1442","article-title":"Decitabine: Development of a DNA methyltransferase inhibitor for hematological malignancies","volume":"4","author":"Lyons","year":"2003","journal-title":"Curr Opin Investig Drugs"},{"key":"key20180108100829_b30-ol-0-0-3253","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1080\/10428190701493910","article-title":"The use of hypomethylating agents in the treatment of hematologic malignancies","volume":"48","author":"Kihslinger","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"key20180108100829_b31-ol-0-0-3253","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1517\/13543784.2011.554822","article-title":"New nucleoside analogs for patients with hematological malignancies","volume":"20","author":"Robak","year":"2011","journal-title":"Expert Opin Investig Drugs"},{"key":"key20180108100829_b32-ol-0-0-3253","doi-asserted-by":"crossref","first-page":"e12994","DOI":"10.1371\/journal.pone.0012994","article-title":"Equitoxic doses of 5-azacytidine and 5-aza-2\u2032deoxycytidine induce diverse immediate and overlapping heritable changes in the transcriptome","volume":"5","author":"Qiu","year":"2010","journal-title":"PLoS One"},{"key":"key20180108100829_b33-ol-0-0-3253","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s00280-007-0531-7","article-title":"Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)","volume":"61","author":"Cashen","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"key20180108100829_b34-ol-0-0-3253","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1196\/annals.1359.037","article-title":"Zebularine: A unique molecule for an epigenetically based strategy in cancer chemotherapy","volume":"1058","author":"Marquez","year":"2005","journal-title":"Ann NY Acad Sci"},{"key":"key20180108100829_b35-ol-0-0-3253","doi-asserted-by":"crossref","first-page":"9775","DOI":"10.3748\/wjg.v20.i29.9775","article-title":"Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years","volume":"20","author":"Panczyk","year":"2014","journal-title":"World J Gastroenterol"},{"key":"key20180108100829_b36-ol-0-0-3253","doi-asserted-by":"crossref","first-page":"46","DOI":"10.4161\/cc.3.1.631","article-title":"Cell cycle checkpoint proteins and cellular response to treatment by anticancer agents","volume":"3","author":"Damia","year":"2004","journal-title":"Cell Cycle"},{"key":"key20180108100829_b37-ol-0-0-3253","doi-asserted-by":"crossref","first-page":"v7","DOI":"10.1093\/annonc\/mdj941","article-title":"Cellular pharmacology of gemcitabine","volume":"17","author":"Mini","year":"2006","journal-title":"Ann Oncol"},{"key":"key20180108100829_b38-ol-0-0-3253","doi-asserted-by":"crossref","first-page":"e50176","DOI":"10.1371\/journal.pone.0050176","article-title":"Algorithmic modeling quantifies the complementary contribution of metabolic inhibitions to gemcitabine efficacy","volume":"7","author":"Kahramano\u011fullari","year":"2012","journal-title":"PLoS One"},{"key":"key20180108100829_b39-ol-0-0-3253","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1007\/s11095-012-0728-2","article-title":"Attenuation of phosphorylation by deoxycytidine kinase is key to acquired gemcitabine resistance in a pancreatic cancer cell line: Targeted proteomic and metabolomic analyses in PK9 cells","volume":"29","author":"Ohmine","year":"2012","journal-title":"Pharm Res"},{"key":"key20180108100829_b40-ol-0-0-3253","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1124\/dmd.111.040790","article-title":"The deaminated metabolite of gemcitabine, 2\u2032,2\u2032-difluorodeoxyuridine, modulates the rate of gemcitabine transport and intracellular phosphorylation via deoxycytidine kinase","volume":"39","author":"Hodge","year":"2011","journal-title":"Drug Metab Dispos"}],"container-title":["Oncology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/ol.2015.3253\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,8]],"date-time":"2018-01-08T07:45:01Z","timestamp":1515397501000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/ol.2015.3253"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,22]]},"references-count":40,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2015,5,22]]},"published-print":{"date-parts":[[2015,8]]}},"alternative-id":["10.3892\/ol.2015.3253"],"URL":"https:\/\/doi.org\/10.3892\/ol.2015.3253","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,22]]}}}